glp-1 receptor brain Frontiers Repurposing glucagon-like peptide-1 receptor agonists

Chemistry Today's November-December 2025 review of peptide synthesis advances explicitly identified "fully aqueous synthesis" and "integration of artificial intelligence to streamline manufacturing processes" as future directions for the field

The introduction of tirzepatide, the first dual agonist targeting both the GLP-1R and the glucose-dependent insulinotropic polypeptide (GIP) receptor, represents a new frontier in incretin-based therapy (Syed, 2022

This ongoing feedback ensures the process stays on track while supporting any necessary lifestyle changes

At least 1.6 million adults in the UK are believed to be using weight-loss injections, while a further 3.3 million are reportedly considering treatment